NeoGenomics Q2 Earnings Call Highlights
NeoGenomics (NASDAQ: NEO) reported Q2 adjusted gross margin of 48.1% and adjusted EBITDA of $14.4 million. It raised 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA to $56 million to $58 million. Management discussed RaDaR ST and PanTracer LBx reimbursement progress, NovaSeq X transitions, and a $316 million convertible note raise. Cash was $145.5 million.
How this was made
The 30-second read
Why it matters
Traders can update valuation and positioning based on the raised revenue and EBITDA guidance, the quantified margin expansion outlook, and the timing of reimbursement decisions that drive RaDaR ST growth.
Market read
A guidance raise with detailed drivers (AUP, volume leverage, Lab of the Future efficiencies) and a clear reimbursement timeline for RaDaR ST are the main tradable catalysts.
What to watch
The DOJ settlement payment affects third-quarter operating cash flow, and RaDaR ST growth is still dependent on pending MolDx indications and adoption beyond early attachment rates.
Background
The piece summarizes NeoGenomics’ Q2 earnings call, focusing on MRD and liquid biopsy commercialization, lab margin initiatives, and updated 2026 outlook.
Ticker impact
NeoGenomics raised 2026 revenue guidance to $802M-$806M and EBITDA to $56M-$58M, citing clinical growth and margin expansion drivers.
Likely positive bias for shares, with volatility around how investors underwrite reimbursement timing and non-clinical revenue normalization.
The article provides specific updated 2026 targets, gross margin and EBITDA changes, and a balance-sheet/cash flow update including DOJ settlement cash impact, all of which can re-rate near-to-mid-term earnings power.
Market effects
Reimbursement progress for tumor-informed MRD (MolDx) and lab automation efficiency are incremental read-throughs for oncology diagnostics peers.
Limited direct regional spillover; primarily US reimbursement and lab operations execution.
Modest global relevance given the company’s US-centric reimbursement pathway and lab network optimization.
Counterpoint
Non-clinical revenue fell 15% and pharma revenue dropped 26%, so the guidance raise may rely on execution that could slip, especially reimbursement decisions into late 2026 and early 2027.
Key entities
- companyNeoGenomics
Cancer-focused genetic and molecular testing services provider; subject of the earnings call highlights and guidance updates.
- regulator/reimbursement bodyMolDx
CMS-related reimbursement program referenced for RaDaR ST reimbursement decisions and pending indications.
- government agencyDepartment of Justice
Legacy self-disclosed matter settlement referenced as a cash flow item affecting Q3.
